When was Sironax founded?

Sironax was founded in 2017 and raised its 1st funding round 5 years after it was founded.

Where is Sironax located?

Sironax is headquartered in Changping District, China.

How many employees does Sironax have?

As of Apr 30, 2026, the latest employee count at Sironax is 60.

Is Sironax a funded company?

Sironax is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Aug 02, 2022.

When was the latest funding round of Sironax?

Sironax's latest funding was a $***** Series B round on Aug 02, 2022, with participation from 14 investors. Its primary sector is Neurology. In China, the Neurology sector has seen $21.6M in funding in 2026 to date.

Where does Sironax rank among its competitors?

Sironax ranks 53rd amongst 452 active competitors, of which 159 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Mission Therapeutics, which secured $13.3M in Oct, 2025.

Who are the top competitors of Sironax?

Sironax's top competitors include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Among them, Mission Therapeutics secured the most recent funding round in October, 2025.

Sironax - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drugs for inflammatory and neurodegenerative diseases. The company is focusing on the development of small molecular compounds for targeting cell death signaling pathways. The company has a portfolio of drugs for inflammatory bowel disease, acute kidney injury, Alzheimer's, and multiple sclerosis.

Website: sironax.com
Email ID: *****@sironax.com
Phone Number: +86 **********

Key Metrics

Founded Year

2017

Location

Changping District, China

Stage

Series B

Total Funding

$200M in 1 round

Latest Funding Round

Series B, Aug 02, 2022, $*****

Investors

Yunfeng Capital & 15 more

Ranked

53^rd among 452 active competitors

Employee Count

60 as on Apr 30, 2026

Similar Companies

Denali Therapeutics & 562 more

View Sironax's full profile

Sironax has raised a total funding of $200M over 1 round. Its latest funding round was a Series B round on Aug 02, 2022 for $*****. 14 investors participated in its latest round. Sironax has 16 institutional investors.

Here is the list of recent funding rounds of Sironax:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 02, 2022	9195239	Series B	8736400	9896352	8177903	2587006

Access funding benchmarks and valuations. Sign up today!

View details of Sironax's funding rounds and investors

The founders of Sironax are Zhiyuan Zhang and Xiaodong Wang.

Here are the details of Sironax's key team members:

Zhiyuan Zhang: Co-Founder of Sironax.
Contact Info: 1 email address
Xiaodong Wang: Co-Founder of Sironax.
Contact Info: 1 email address

View details of Sironax's Founder profiles and Board Members

Sironax's employee count trend

Sironax has 60 employees as of Apr 26. Here is Sironax's employee count trend over the years:

Uncover Sironax's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sironax include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Here is the list of Top 10 competitors of Sironax, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
3rd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
4th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	New Enterprise Associates, Blackstone & 17 others	67/100
5th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
6th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	ATW Partners, Sanofi & 5 others	65/100
7th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$115M	RA Capital Management, SV Health Investors ... & 13 others	64/100
8th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 6 others	63/100
9th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	63/100
10th	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	62/100
53rd	Sironax 2017, Changping District (China), Series B	Developer of drugs for inflammatory and neurodegenerative diseases	$200M	Temasek, Yunfeng Capital & 14 others	54/100